Financial results - NOVISANTEPHARM SRL

Financial Summary - Novisantepharm Srl
Unique identification code: 15469324
Registration number: J12/1382/2003
Nace: 4646
Sales - Ron
-
Net Profit - Ron
165
Employee
The most important financial indicators for the company Novisantepharm Srl - Unique Identification Number 15469324: sales in 2023 was - euro, registering a net profit of 165 euro and having an average number of employees. Firma isi desfasoara activitatea in domeniul Comert cu ridicata al produselor farmaceutice having the NACE code 4646.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Novisantepharm Srl

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 71.452 69.846 123.557 202.803 30.828 20.499 6.719 0 0 0
Total Income - EUR 71.452 69.846 123.557 202.804 30.829 20.500 6.740 1 1 1.699
Total Expenses - EUR 72.824 79.426 123.089 160.592 26.618 12.196 7.566 2.449 3.557 1.498
Gross Profit/Loss - EUR -1.372 -9.581 468 42.211 4.211 8.304 -826 -2.448 -3.556 201
Net Profit/Loss - EUR -3.947 -10.827 -1.999 40.207 3.286 7.689 -1.028 -2.448 -3.556 165
Employees 1 1 1 1 1 0 0 0 0 0
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.

Check the financial reports for the company - Novisantepharm Srl

Rating financiar

Financial Rating -
Novisantepharm Srl

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Novisantepharm Srl

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Novisantepharm Srl

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Novisantepharm Srl

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Novisantepharm Srl - CUI 15469324

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 40.932 19.820 142 0 0 0 0 0 0 0
Current Assets 65.166 46.413 44.291 55.368 14.567 21.581 7.311 4.669 2.494 3.900
Inventories 0 0 27 26 26 0 0 0 0 0
Receivables 63.565 42.285 42.353 50.156 10.847 19.363 5.388 2.329 481 2.270
Cash 1.600 4.129 1.911 5.186 3.694 2.219 1.923 2.341 2.012 1.630
Shareholders Funds 20.919 10.267 8.163 48.232 11.211 18.683 7.396 4.784 1.242 1.403
Social Capital 49 49 49 48 95 93 91 89 89 89
Debts 85.179 58.134 38.149 8.860 3.356 4.345 1.268 1.240 1.252 3.743
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "4646 - 4646"
CAEN Financial Year 4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 3.900 euro in 2023 which includes Inventories of 0 euro, Receivables of 2.270 euro and cash availability of 1.630 euro.
The company's Equity was valued at 1.403 euro, while total Liabilities amounted to 3.743 euro. Equity increased by 165 euro, from 1.242 euro in 2022, to 1.403 in 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Novisantepharm Srl

Comments - Novisantepharm Srl

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.